RE
CRSP icon

RBC Europe’s CRISPR Therapeutics CRSP Stock Holding History

RBC Europe’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$10K Sell
170
-275
-62% -$16.2K ﹤0.01% 496
2022
Q1 		$28K Buy
445
+275
+162% +$17.3K ﹤0.01% 416
2021
Q4 		$13K Sell
170
-350
-67% -$30.6K ﹤0.01% 500
2021
Q3 		$58.2K Buy
520
+41
+9% +$5.15K ﹤0.01% 544
2021
Q2 		$77.5K Buy
479
+315
+192% +$38.3K ﹤0.01% 486
2021
Q1 		$20K Buy
164
+124
+310% +$18.7K ﹤0.01% 762
2020
Q4 		$6.12K Buy
+40
New +$4.73K ﹤0.01% 946
2020
Q1 		– Sell
-64
Closed -$3.9K – 1058
2019
Q4 		$3.9K Hold
64
– – ﹤0.01% 920
2019
Q3 		$2.62K Hold
64
– – ﹤0.01% 945
2019
Q2 		$3.01K Buy
+64
New +$2.56K ﹤0.01% 960
2017
Q4 		– Sell
-600
Closed -$10.7K – 1140
2017
Q3 		$10.7K Buy
+600
New +$10.9K ﹤0.01% 817

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

RBC Europe's CRSP Position: Q2 2022 in Review

RBC Europe reduced its CRISPR Therapeutics (CRSP) stake by 62% in Q2 2022, selling an estimated $16.2K and leaving 170 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #496.

RBC Europe first reported a position in CRSP in Q3 2017 and has held it in 11 quarters since. The position peaked at $77.5K in Q2 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • RBC Europe held 170 shares of CRISPR Therapeutics worth $10K as of Q2 2022.
  • RBC Europe sold 275 CRISPR Therapeutics shares in Q2 2022, an estimated $16.2K.
  • CRISPR Therapeutics made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #496 holding.
  • RBC Europe first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 11 quarters since.
  • RBC Europe's CRISPR Therapeutics position peaked at $77.5K in Q2 2021.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.